Cancer Management and Research (May 2020)
Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma
Abstract
Nityam Rathi, Benjamin L Maughan, Neeraj Agarwal, Umang Swami Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USACorrespondence: Neeraj AgarwalGenitourinary Oncology Program, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USAEmail [email protected] SwamiDepartment of Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USAEmail [email protected]: Cabozantinib is an oral, tyrosine-kinase inhibitor with potent activity against VEGFR2 and MET, along with multiple other tyrosine kinases involved in cancer development and progression. Herein, we will focus on preclinical and clinical studies leading to the approval of cabozantinib in advanced renal cell carcinoma and hepatocellular carcinoma. Covered studies include NCT01100619, CABOSUN, METEOR, NCT00940225 and the CELESTIAL trial. Finally, we review future directions of cabozantinib development by highlighting some ongoing clinical trials.Keywords: cabozantinib, renal cell carcinoma, hepatocellular carcinoma, kidney cancer, liver cancer, cabozantinib resistance mechanism
